Manuel A de la Torre1, Juan Buades-Mateu1, Pedro A de la Rosa2, Alberto Lué3, Francisco J Bustamante4, María T Serrano3, Milagros Testillano4, Sara Lorente3, Juan I Arenas5, Cristina Gil4, Mercedes Iñarrairaegui1,6, Bruno Sangro1,6. 1. Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain. 2. Preventive Medicine, Complejo Hospitalario de Navarra, Pamplona, Spain. 3. Gastroenterology and Hepatology, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain. 4. Liver Unit, Hospital Universitario Cruces, Baracaldo, Spain. 5. Gastroenterology and Hepatology, Hospital Universitario Donostia, San Sebastian, Spain. 6. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Pamplona, Spain.
Abstract
BACKGROUND & AIMS: Sorafenib (SOR) is the standard of care for patients with hepatocellular carcinoma (HCC) and portal vein invasion (PVI), based on the results of phase 3 trials. However, radioembolization (RE) using yttrium-90 microspheres has been shown to achieve higher response rates and better survival in large cohorts and phase 2 trials. This study aimed to compare survival of HCC patients with PVI treated by RE or SOR. METHODS: Survival among patients with HCC and PVI treated with RE or SOR in four Spanish hospitals between 2005 and 2013 was analysed retrospectively. Kaplan-Meier survival curves were plotted and baseline variables tested for prognostic value using the log-rank test. A multivariate prognostic model including variables identified in the univariate analysis and adjusted by a propensity score based on factors that may determine the probability of exposure to RE was generated using Cox regression analyses. RESULTS: After a median follow-up of 6 months, 60 deaths had occurred: 38 and 22 in SOR and RE groups respectively. Median survival was 6.7 months (95%CI 5.2-8.1 months) for the entire cohort, and 8.8 months (95%CI 1.8-15.8) in the RE group and 5.4 months (95%CI 2.7-8.1) in the SOR group (P = 0.047). The difference in survival was still statistically significant when 13 patients in the RE group who started SOR after a median time of 8 months were censored from the analysis. CONCLUSIONS: In a cohort of patients with HCC and PVI treatment with RE was associated with a more prolonged survival compared with SOR.
BACKGROUND & AIMS:Sorafenib (SOR) is the standard of care for patients with hepatocellular carcinoma (HCC) and portal vein invasion (PVI), based on the results of phase 3 trials. However, radioembolization (RE) using yttrium-90 microspheres has been shown to achieve higher response rates and better survival in large cohorts and phase 2 trials. This study aimed to compare survival of HCC patients with PVI treated by RE or SOR. METHODS: Survival among patients with HCC and PVI treated with RE or SOR in four Spanish hospitals between 2005 and 2013 was analysed retrospectively. Kaplan-Meier survival curves were plotted and baseline variables tested for prognostic value using the log-rank test. A multivariate prognostic model including variables identified in the univariate analysis and adjusted by a propensity score based on factors that may determine the probability of exposure to RE was generated using Cox regression analyses. RESULTS: After a median follow-up of 6 months, 60 deaths had occurred: 38 and 22 in SOR and RE groups respectively. Median survival was 6.7 months (95%CI 5.2-8.1 months) for the entire cohort, and 8.8 months (95%CI 1.8-15.8) in the RE group and 5.4 months (95%CI 2.7-8.1) in the SOR group (P = 0.047). The difference in survival was still statistically significant when 13 patients in the RE group who started SOR after a median time of 8 months were censored from the analysis. CONCLUSIONS: In a cohort of patients with HCC and PVI treatment with RE was associated with a more prolonged survival compared with SOR.
Authors: Manuel de la Torre-Aláez; Carlota Jordán-Iborra; Andrea Casadei-Gardini; José Ignacio Bilbao; Macarena Rodriguez-Fraile; Lidia Sancho; Delia D'Avola; José Ignacio Herrero; Mercedes Iñarrairaegui; Bruno Sangro Journal: Cardiovasc Intervent Radiol Date: 2020-03-12 Impact factor: 2.740
Authors: Boris Gorodetski; Julius Chapiro; Ruediger Schernthaner; Rafael Duran; MingDe Lin; Howard Lee; David Lenis; Elizabeth A Stuart; Bareng Aletta Sanny Nonyane; Vasily Pekurovsky; Anobel Tamrazi; Bernhard Gebauer; Todd Schlachter; Timothy M Pawlik; Jean-Francois Geschwind Journal: Eur Radiol Date: 2016-06-08 Impact factor: 5.315
Authors: Charlotte E Costentin; Cristina R Ferrone; Ronald S Arellano; Suvranu Ganguli; Theodore S Hong; Andrew X Zhu Journal: Liver Cancer Date: 2017-10-19 Impact factor: 11.740
Authors: Joseph C Ahn; Marie Lauzon; Michael Luu; Marc L Friedman; Kambiz Kosari; Nicholas Nissen; Shelly C Lu; Lewis R Roberts; Amit G Singal; Ju Dong Yang Journal: J Nucl Med Date: 2021-04-09 Impact factor: 11.082
Authors: Clemens Schotten; Lars P Bechmann; Paul Manka; Jens Theysohn; Alexander Dechêne; Amr El Fouly; Francesco Barbato; Ursula Neumann; Sonia Radünz; Svenja Sydor; Dominik Heider; Marino Venerito; Ali Canbay; Guido Gerken; Ken Herrmann; Heiner Wedemeyer; Jan Best Journal: Liver Cancer Date: 2019-07-29 Impact factor: 11.740
Authors: Sarah Walcott-Sapp; Scott Naugler; Jeong Youn Lim; Jesse Wagner; Susan L Orloff; Khashayar Farsad; Kenneth J Kolbeck; John Kaufman; Erin Maynard; C Kristian Enestvedt; Skye C Mayo; Kevin G Billingsley Journal: J Gastrointest Oncol Date: 2018-12
Authors: Young Youn Cho; Minjong Lee; Hyo-Cheol Kim; Jin Wook Chung; Yun Hwan Kim; Geum-Youn Gwak; Si Hyun Bae; Do Young Kim; Jeong Heo; Yoon Jun Kim Journal: PLoS One Date: 2016-05-05 Impact factor: 3.240